Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.

[1]  K. Yanagihara,et al.  Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. , 2022, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  E. Kuijper,et al.  European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  K. Garey,et al.  Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Kelly,et al.  ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections , 2021, The American journal of gastroenterology.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[6]  D. Paredes-Sabja,et al.  Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection , 2021, Nature Communications.

[7]  A. Ananthakrishnan,et al.  Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review , 2021, Therapeutic advances in gastroenterology.

[8]  J. Benes,et al.  Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection-an observational cohort study. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  M. Gelfand,et al.  Fidaxomicin Compared With Oral Vancomycin for the Treatment of Severe Clostridium difficile–Associated Diarrhea: A Retrospective Review , 2020, Hospital pharmacy.

[10]  M. Usui.  One Health approach to Clostridioides difficile in Japan. , 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[11]  S. McGowan,et al.  Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection , 2019, Nature Microbiology.

[12]  J. Dahlerup,et al.  Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. , 2019, Gastroenterology.

[13]  T. Iqbal,et al.  Effect of using fidaxomicin on recurrent Clostridium difficile infection. , 2019, The Journal of hospital infection.

[14]  Kazuaki Matsumoto,et al.  Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. , 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[15]  K. Tateda,et al.  Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. , 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  H. Williams,et al.  Clostridium difficile infection and antibiotic-associated diarrhoea , 2018, Clinical medicine.

[17]  C. Donskey,et al.  Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice , 2018, Antimicrobial Agents and Chemotherapy.

[18]  N. Ajami,et al.  Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice , 2018, Antimicrobial Agents and Chemotherapy.

[19]  C. Pothoulakis,et al.  Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity , 2017, Antimicrobial Agents and Chemotherapy.

[20]  H. Nair,et al.  Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis , 2017, Journal of global health.

[21]  M. Falagas,et al.  Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. , 2016, International journal of antimicrobial agents.

[22]  K. Garey,et al.  A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin , 2016, Annals of Clinical Microbiology and Antimicrobials.

[23]  L. Valiquette,et al.  Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Nicolau,et al.  Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin , 2015, Infection Control & Hospital Epidemiology.

[25]  Laichun Lu,et al.  Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis , 2015, PloS one.

[26]  S. Erickson,et al.  Chronic kidney disease and end‐stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta‐analysis , 2015, International journal of clinical practice.

[27]  G. Rennert,et al.  Statins use and risk of mortality in patient with Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  L. Valiquette,et al.  Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review , 2014, PloS one.

[29]  T. Riley,et al.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[30]  S. W. Park,et al.  The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients , 2013, Alimentary pharmacology & therapeutics.

[31]  C. Donskey,et al.  Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. , 2013, The Journal of antimicrobial chemotherapy.

[32]  A. Sonenshein,et al.  Fidaxomicin Inhibits Spore Production in Clostridium difficile , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Mark A. Miller,et al.  Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  T. Louie,et al.  Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  D. Gerding,et al.  Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Crook,et al.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[37]  P. Sears,et al.  Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. , 2011, Journal of medical microbiology.

[38]  P. Sears,et al.  Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile , 2011, Antimicrobial Agents and Chemotherapy.

[39]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[40]  C. Nord,et al.  Metronidazole is still the drug of choice for treatment of anaerobic infections. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Mark H. Wilcox,et al.  Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.

[42]  Stuart Johnson.  Recurrent Clostridium difficile infection: causality and therapeutic approaches. , 2009, International journal of antimicrobial agents.

[43]  K. Garey,et al.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.

[44]  S. Routhier,et al.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  D. Musher,et al.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  M. Stevenson,et al.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. , 2003, The Journal of antimicrobial chemotherapy.

[47]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[48]  C. Surawicz,et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.

[49]  T. Oshima,et al.  Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis , 2017, Journal of Gastroenterology.